Following dendrimer PEGylation (PEG5000 modified with a synthetic luteinizing-hormone-releasing hormone (LHRH) analogue) provided greater particle stability and active targeting to specific cancer cells, which led to increased intratumoral accumulation and enhanced suppression of Bcl-2 mRNA. Here, BCL2 is linked to cancer.